FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211093907> ?p ?o ?g. }

• W3211093907 endingPage "386" @default.
• W3211093907 startingPage "378" @default.
• W3211093907 abstract "Due to the vague symptomatology of the disease and a lack of effective screening methods, most patients with epithelial ovarian cancer (EOC) present late in their disease. Despite advances in chemotherapeutic agents, the prognosis of these patients has uniformly been extremely poor. Although cisplatin-based chemotherapy regimens induce responses in most of these patients, the patients invariably experience disease progression or relapses. In an attempt to improve the treatment outcome using a different therapeutic approach, immunotherapy was investigated nearly 20 years ago. Many tumor antigens that are potentially suitable for specific immunotherapy were identified, and many immunotherapeutic approaches were attempted. However, although some responses were observed, the results from clinical studies were generally disappointing. Recent advances in immunoengineering and successes observed among patients treated for refractory/relapsed hematologic malignancies have rekindled the interest to revisit specific cellular immunotherapy in EOC. In this review, we provide the rationale for immunotherapy of EOC, discuss the results of some of the historical studies on the use of cellular immunotherapy in EOC, outline the principles of modern immunoengineering that could be applied to treat the disease, and propose the re-evaluation of the cancer-testis antigen, Sperm protein 17, for targeting by using modern immunoengineering technology. Due to the vague symptomatology of the disease and a lack of effective screening methods, most patients with epithelial ovarian cancer (EOC) present late in their disease. Despite advances in chemotherapeutic agents, the prognosis of these patients has uniformly been extremely poor. Although cisplatin-based chemotherapy regimens induce responses in most of these patients, the patients invariably experience disease progression or relapses. In an attempt to improve the treatment outcome using a different therapeutic approach, immunotherapy was investigated nearly 20 years ago. Many tumor antigens that are potentially suitable for specific immunotherapy were identified, and many immunotherapeutic approaches were attempted. However, although some responses were observed, the results from clinical studies were generally disappointing. Recent advances in immunoengineering and successes observed among patients treated for refractory/relapsed hematologic malignancies have rekindled the interest to revisit specific cellular immunotherapy in EOC. In this review, we provide the rationale for immunotherapy of EOC, discuss the results of some of the historical studies on the use of cellular immunotherapy in EOC, outline the principles of modern immunoengineering that could be applied to treat the disease, and propose the re-evaluation of the cancer-testis antigen, Sperm protein 17, for targeting by using modern immunoengineering technology." @default.
• W3211093907 created "2021-11-08" @default.
• W3211093907 creator A5009313914 @default.
• W3211093907 creator A5033591499 @default.
• W3211093907 creator A5046533826 @default.
• W3211093907 creator A5049565831 @default.
• W3211093907 date "2021-12-01" @default.
• W3211093907 modified "2023-10-14" @default.
• W3211093907 title "Sperm protein 17 targeting for epithelial ovarian cancer treatment in the era of modern immunoengineering" @default.
• W3211093907 cites W1605109223 @default.
• W3211093907 cites W1619537825 @default.
• W3211093907 cites W1748167540 @default.
• W3211093907 cites W1804864865 @default.
• W3211093907 cites W1943191147 @default.
• W3211093907 cites W1966598152 @default.
• W3211093907 cites W1977642966 @default.
• W3211093907 cites W1986174251 @default.
• W3211093907 cites W1990159887 @default.
• W3211093907 cites W1990834696 @default.
• W3211093907 cites W2003197307 @default.
• W3211093907 cites W2006478843 @default.
• W3211093907 cites W2007988465 @default.
• W3211093907 cites W2008188798 @default.
• W3211093907 cites W2015074260 @default.
• W3211093907 cites W2015192757 @default.
• W3211093907 cites W2017248792 @default.
• W3211093907 cites W2018235031 @default.
• W3211093907 cites W2020247695 @default.
• W3211093907 cites W2027726380 @default.
• W3211093907 cites W2030725641 @default.
• W3211093907 cites W2033016734 @default.
• W3211093907 cites W2042989579 @default.
• W3211093907 cites W2046058683 @default.
• W3211093907 cites W2046079502 @default.
• W3211093907 cites W2051549641 @default.
• W3211093907 cites W2063221670 @default.
• W3211093907 cites W2064272625 @default.
• W3211093907 cites W2065249718 @default.
• W3211093907 cites W2069892840 @default.
• W3211093907 cites W2070850731 @default.
• W3211093907 cites W2075956854 @default.
• W3211093907 cites W2077633929 @default.
• W3211093907 cites W2079161585 @default.
• W3211093907 cites W2079565358 @default.
• W3211093907 cites W2081878465 @default.
• W3211093907 cites W2094666871 @default.
• W3211093907 cites W2096494694 @default.
• W3211093907 cites W2101582566 @default.
• W3211093907 cites W2102543522 @default.
• W3211093907 cites W2104663221 @default.
• W3211093907 cites W2105459360 @default.
• W3211093907 cites W2106057807 @default.
• W3211093907 cites W2113122060 @default.
• W3211093907 cites W2128746885 @default.
• W3211093907 cites W2129978376 @default.
• W3211093907 cites W2133629127 @default.
• W3211093907 cites W2139879995 @default.
• W3211093907 cites W2140373765 @default.
• W3211093907 cites W2154056804 @default.
• W3211093907 cites W2154503877 @default.
• W3211093907 cites W2168572010 @default.
• W3211093907 cites W2174510671 @default.
• W3211093907 cites W2313365286 @default.
• W3211093907 cites W2318069727 @default.
• W3211093907 cites W2403289604 @default.
• W3211093907 cites W2434899782 @default.
• W3211093907 cites W2596760231 @default.
• W3211093907 cites W2742806387 @default.
• W3211093907 cites W2751871114 @default.
• W3211093907 cites W2766080828 @default.
• W3211093907 cites W2791024856 @default.
• W3211093907 cites W2795536362 @default.
• W3211093907 cites W2888654481 @default.
• W3211093907 cites W2889302413 @default.
• W3211093907 cites W2894424410 @default.
• W3211093907 cites W2896393991 @default.
• W3211093907 cites W2896528779 @default.
• W3211093907 cites W2943335541 @default.
• W3211093907 cites W2951714360 @default.
• W3211093907 cites W2961329554 @default.
• W3211093907 cites W2965330503 @default.
• W3211093907 cites W2996091824 @default.
• W3211093907 cites W3024978145 @default.
• W3211093907 cites W3036364440 @default.
• W3211093907 cites W3120355176 @default.
• W3211093907 cites W3163701621 @default.
• W3211093907 cites W3165210197 @default.
• W3211093907 cites W4211203170 @default.
• W3211093907 cites W4245049346 @default.
• W3211093907 doi "https://doi.org/10.1016/j.omto.2021.10.010" @default.
• W3211093907 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8604669" @default.
• W3211093907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34853809" @default.
• W3211093907 hasPublicationYear "2021" @default.
• W3211093907 type Work @default.
• W3211093907 sameAs 3211093907 @default.
• W3211093907 citedByCount "1" @default.
• W3211093907 countsByYear W32110939072023 @default.
• W3211093907 crossrefType "journal-article" @default.

• next